PHARMACOLOGY UPDATE

Revumenib Tablets (Revuforj)

January 15, 2025

The U.S. Food and Drug Administration has approved the first menin inhibitor, revumenib, for the treatment of relapsing or refractory acute leukemia with a lysine methyltransferase 2A gene (also known as the mixed lineage leukemia gene) translocation in adults and pediatric patients.

Issue Date: January 15, 2025

Table of Contents

Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau and advisory board for AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Novo Nordisk, and Renalytix; is on the speakers bureau for Eli Lilly; is on the advisory board for Abbott Diabetes, Phathom, Sanofi, Kowa, Haleon, and Biolinq; and is a stockholder with Paracrine. The relevant financial relationships listed for this individual have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements